This is the authors' abstract. We don't add key points for this paper.
1YOPHILIZED factor VIII concentrates have beJ come the treatment of choice for factor VIII-deficient patients with hemophilia. The cost of such treatment is high, primarily because under normal conditions of collection and preparation, factor VIII procoagulant activity (VIIIC, sec Table 1 for terms and definitions1) is unstable and as much as 80 per cent of the activity is lost during the purification procedure. Recently, we have reported that factor VIIIC activity is stabilized when blood is collected into heparin rather than citrate anticoagulant, and we have shown that the cryoprecipitates obtained from heparinized blood contain 80 per cent of the VIIIC . . .
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Rock et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: